Treatment Strategies for NSCLC with Non-Actionable Mutations
Jun 24, 2024 · How do treatment approaches differ between patients with actionable vs non-actionable mutations? Briefly outline your general treatment approach for NSCLC with non-actionable mutations.
Over the past decade, immunotherapy- based regimens have transformed the treatment landscape for non- small cell lung cancer (NSCLC) and are currently first- line therapy options for eligible patients …
New promises and challenges in the treatment of advanced ... - The Lancet
Aug 6, 2024 · Targeted therapies and immunotherapies have radically improved treatment for advanced non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver mutations …
Nature Medicine Publishes Results of Phase II Study of ... - BioSpace
Aug 20, 2025 · The publication highlighted initial findings from the Phase II OptiTROP-Lung01 study, evaluating the efficacy and safety results of sac-TMT in combination with tagitanlimab as a first-line …
How to make the best use of immunotherapy as first-line treatment …
Antibodies that target programmed death 1 (PD-1) or its ligand [programmed death ligand 1 (PD-L1)] have become a mainstay of first-line treatment of advanced/metastatic non-small-cell lung cancer …
How to Treat Metastatic Non-Small Cell Lung Cancer (NSCLC) Without …
May 12, 2025 · Our discussion centered around the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings. We began by emphasizing …
Real-world treatment and outcomes for EGFR WT advanced/metastatic …
May 8, 2025 · Non-small cell lung cancer (NSCLC) is the most common type; most cases are advanced/metastatic at diagnosis. Available first and second lines of treatment include platinum …
Phase III, Open-label, First-line Study of Dato-DXd in Combination …
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared …
Clinical Strategies for Advanced Non–Small Cell Lung Cancer
Jun 17, 2025 · Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non–small-cell lung cancer without …
Initial systemic therapy for advanced non-small cell lung cancer ...
Aug 8, 2025 · Although targeted therapies are now the preferred first-line option for many oncogene-driven NSCLCs (such epidermal growth factor receptor-mutant, anaplastic lymphoma kinase - …